Oncology Meeting Innovations held it’s 2nd Annual Global Summit on Hematologic Malignancies: Europe in Lisbon, Portugal from February 14 -16, 2019. Dr. Giovanni Martinelli of Istituto Scientifico Romagnolo, Dr. Maria-Victoria Mateos of University of Salmanaca and Dr. Davide Rossi of the Institute of Oncology Research chaired the Summit. Tumor types covered within the agenda included CLL, lymphoma, multiple myeloma and acute leukemias. Presentations and discussion focused on recent data and emerging trends in hematologic malignancies, with an emphasis on BTK inhibition in CLL and lymphoma, utilizing and optimizing CAR-T therapy, FLT3 inhibition in AML and sequencing of treatments across hematologic malignancies.
Assembly of the summit fosters discussion and debate around the development of treating hematologic malignancies. “Due to rapid advances in cell biology, genomics, drug discovery and cellular therapeutics, forums that allow scientific exchange and debate are vital to improving the development and implementation of the recent advances,” said Dava’s Chief Medical Officer, Dr. John Eckardt. “The participants had a lively discussion on how these advances can be safely integrated into the care of patients in Europe and around the world.” As part of the discussion regarding new developments in the treatment of hematologic malignancies, faculty and participants also focused on prognostic and diagnostic testing. “There was focused discussion on better methods for assessing response including different techniques to assess MRD and the relevance of MRD in different hematologic cancers,” Eckardt said.
We thank our industry partners Janssen Oncology, Astellas and Loxo Oncology for their commitment to OMI’s mission to improve the dissemination of knowledge between researchers, innovators and implementers in the treatment of